Welcome to our dedicated page for Chemomab Therapeutics Ltd. American Depositary Share news (Ticker: CMMB), a resource for investors and traders seeking the latest updates and insights on Chemomab Therapeutics Ltd. American Depositary Share stock.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) is a clinical-stage biotechnology company focused on the development of innovative therapeutics to treat fibro-inflammatory diseases with significant unmet medical needs. The company's proprietary platform centers on CM-101, a first-in-class monoclonal antibody that targets the protein CCL24, a key regulator of inflammatory and fibrotic pathways in several severe diseases.
CM-101 has demonstrated potential in disrupting the underlying biology of fibrosis through a novel mechanism of action. The company is actively advancing CM-101 through multiple Phase 2 clinical trials aimed at treating rare and life-threatening conditions such as primary sclerosing cholangitis (PSC), non-alcoholic steatohepatitis (NASH), and systemic sclerosis (SSc). In recognition of its innovative approach, CM-101 has been granted Orphan Drug designation in both the U.S. and the European Union, and it recently received Fast Track designation from the FDA for PSC treatment.
Chemomab has reported encouraging preliminary results from these trials, which indicate that CM-101 is safe and effective in interfering with fibrotic and inflammatory pathways. The company has secured robust intellectual property protections for CM-101, with patents granted or pending in major territories worldwide, ensuring proprietary rights for the treatment of multiple indications until at least 2038.
Recent highlights from Chemomab include:
- Completion of patient enrollment in the Phase 2 PSC trial, with topline data expected mid-2024.
- Granting of new patents in Brazil, Israel, and Europe that further protect the use of CM-101 in treating liver diseases and other conditions.
- Publication of peer-reviewed studies validating the role of CCL24 in driving PSC and SSc pathologies, and the potential of CM-101 as a therapeutic intervention.
- Presentations at major scientific conferences including EASL 2024 and the Gordon Research Conference, showcasing novel translational assays and proteomic profiling studies that support the efficacy of CM-101.
As Chemomab continues to advance its clinical programs and expand its scientific understanding of fibro-inflammatory diseases, it remains committed to addressing the urgent need for effective treatments in these challenging medical areas.
Chemomab Therapeutics announced new publications reinforcing the clinical potential of its CCL24-neutralizing antibody, CM-101, in treating primary sclerosing cholangitis (PSC). A study published in the International Journal of Molecular Science used machine learning to analyze proteomic profiles from PSC patient sera, confirming that high levels of CCL24 are linked to PSC severity and cirrhosis. This highlights the possibility of CM-101 as an effective therapy. A second study in Drug Safety reported that CM-101 showed good tolerability and reduced biomarkers of inflammation and fibrosis in Phase 1 trials. Topline data from the Phase 2 PSC trial is expected mid-2024.
Chemomab Therapeutics shared promising data at EASL 2024 and the Gordon Research Conference, showcasing the potential of CM-101 as a novel treatment for Primary Sclerosing Cholangitis (PSC). The studies highlighted CM-101's anti-fibrotic activity, evidenced by reduced liver fibroblast activation in ex vivo assays using patient samples. New translational data confirmed CM-101's disease-modifying effects in PSC. Proteomic profiling and machine learning developed a protein signature predicting PSC severity, reinforcing the therapeutic targeting of CCL24. These findings are pivotal as Chemomab approaches topline results from its Phase 2 PSC trial.
Chemomab Therapeutics (Nasdaq: CMMB), a clinical-stage biotech firm focusing on fibro-inflammatory diseases, has announced its participation in two significant scientific conferences. At the Gordon Research Conference on Chemotactic Cytokines (June 2-7, 2024, Portland, Maine), Prof. Amnon Peled will present on CCL24's role in liver fibrosis and inflammation. At the EASL Congress 2024 (June 5-8, 2024, Milan, Italy), Chemomab's team will present multiple posters on CM-101's anti-fibrotic activity and its potential for primary sclerosing cholangitis. Chemomab's corporate development team will also attend the BIO International Convention in San Diego (June 3-6, 2024) for partnering opportunities.
Chemomab Therapeutics announced its first quarter 2024 financial results and corporate update, highlighting early completion of patient enrollment in the CM-101 Phase 2 trial for primary sclerosing cholangitis, peer-reviewed publications validating the role of CCL24, and significant catalysts expected in late 2024/early 2025. The company also reported new patents granted in the E.U., Brazil, and Israel, and hosted an expert PSC webinar. Financially, Chemomab's cash position was $16.0 million as of March 31, 2024, with decreased R&D and G&A expenses.
Chemomab Therapeutics (Nasdaq: CMMB) has been granted a 180-day extension by Nasdaq to regain compliance with the minimum bid price rule. The company has until November 4, 2024, to ensure that the closing bid price of its American Depositary Shares (ADSs) is at least $1.00 per ADS for a minimum of 10 consecutive trading days. If the requirement is met, Nasdaq will confirm compliance, allowing Chemomab to maintain its listing on the Nasdaq Capital Market under the symbol 'CMMB'.
Chemomab Therapeutics (Nasdaq: CMMB) will have Dr. Adi Mor, the CEO, present at the Aegis Virtual Conference on May 7, 2024, discussing innovative therapeutics for fibro-inflammatory diseases. The presentation will be webcast live, offering further insights into the company's endeavors.
FAQ
What is the current stock price of Chemomab Therapeutics Ltd. American Depositary Share (CMMB)?
What is the market cap of Chemomab Therapeutics Ltd. American Depositary Share (CMMB)?
What is Chemomab Therapeutics Ltd.?
What is CM-101?
What diseases is CM-101 being tested for?
Has CM-101 received any special designations from regulatory authorities?
When are the results from the Phase 2 PSC trial expected?
What recent achievements has Chemomab announced?
What makes CM-101 unique?
What is the significance of the new patents granted to Chemomab?
Where has Chemomab presented its research?
How does CM-101 work?
